Home > Boards > US Listed > Biotechs > Geron Corp. (GERN)

Corning Incorporated Introduces New Synthemax™ Synthetic Surface to

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
KarinCA Member Profile
Member Level 
Followed By 541
Posts 24,586
Boards Moderated 2
Alias Born 11/16/07
160x600 placeholder
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 10/17/2019 4:10:05 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2019 6:57:30 AM
Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes GlobeNewswire Inc. - 10/10/2019 5:30:00 PM
Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis GlobeNewswire Inc. - 9/30/2019 4:19:00 PM
Geron to Present at 2019 Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 4:18:00 PM
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 8/22/2019 4:18:00 PM
Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes GlobeNewswire Inc. - 8/8/2019 8:08:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/1/2019 4:26:07 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/1/2019 4:09:05 PM
Geron Corporation Reports Second Quarter 2019 Financial Results and Recent Events GlobeNewswire Inc. - 8/1/2019 4:05:00 PM
Geron to Announce Second Quarter Financial Results on August 1, 2019 GlobeNewswire Inc. - 7/25/2019 8:00:00 AM
Geron Enhances Oncology Expertise to Advance Corporate Objectives GlobeNewswire Inc. - 7/18/2019 4:15:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2019 7:08:08 PM
Geron Appoints Vice President, Human Resources GlobeNewswire Inc. - 6/20/2019 4:27:00 PM
Geron Reports Two Imetelstat Data Presentations at European Hematology Association Annual Congress GlobeNewswire Inc. - 6/17/2019 8:20:00 AM
Geron to Webcast KOL Event on June 25, 2019 GlobeNewswire Inc. - 6/10/2019 4:45:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 7:26:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 7:25:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 7:24:54 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 7:24:18 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 7:23:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 7:19:12 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/7/2019 5:22:37 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/16/2019 9:26:22 AM
Geron Announces Two Presentations on Imetelstat at Upcoming European Hematology Association Annual Congress GlobeNewswire Inc. - 5/16/2019 9:05:49 AM
KarinCA Member Level  Thursday, 03/04/10 03:42:36 AM
Re: None
Post # of 6806 
Corning Incorporated Introduces New Synthemax™ Synthetic Surface to Enhance and Support Stem Cell Growth
Revolutionary Surface Demonstrates Continued Commitment to Delivering Products that Enable Advanced Drug Discovery Research

http://www.corning.com/news_center/news_releases/2010/2010030302.aspx

An excerpt:
Quote:
CORNING, N.Y., March 03, 2010 – Corning Incorporated (NYSE: GLW) today introduced the Corning® Synthemax™ surface, a novel synthetic surface that supports the growth and differentiation of stem cells. The surface is being commercialized as a result of Corning’s ongoing collaboration with Geron Corporation (Nasdaq: GERN). This development enables researchers to take the next step toward scalable and cost-effective manufacturing of stem cells for potential therapies in the treatment of degenerative diseases.

Data presented by Corning and Geron at the World Stem Cell Summit in Baltimore in September 2009 demonstrated multi-passage growth of multiple undifferentiated human stem cell lines and the subsequent differentiation of one of these cell lines into cardiomyocytes. This is the first time the differentiation has been demonstrated with the results presented on a synthetic surface. The growth and differentiation of stem cells on the Synthemax surface is robust and reproducible, an important condition for the large-scale production of cells and therapeutic development.

“The commercialization of the Synthemax surface is a clear proof point of the success of our collaboration with Geron,” said Dr. Jeff Mooney, director of commercial technology for Corning Life Sciences. “By leveraging our unique expertise in materials and surfaces, as well as Geron’s advanced therapeutic stem cell techniques, we have been able to develop what we believe is the first and only synthetic surface in the world to enable this level of stem cell growth and differentiation.”




GLTA... KarinCA ;)

"Be kinder than necessary, for everyone you meet is fighting some kind of battle."

Just my opinion. Your own entry and exit points will determine whether or not you made a good trade
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist